Clinical trials
Meningioma clinical trials
Below are recruiting meningioma clinical trials, each written for real people, not researchers. We’re tracking 64 recruiting studies, each written for real people, not researchers, below.
Recruiting studies
- NCT04082520RecruitingPhase 2
Lutathera for non-surgery meningioma that keeps growing
This Phase 2 study tests Lutathera to treat meningioma that cannot be safely removed with surgery and is still growing after radiation. It uses a special scan to make sure the tumor has the right target, and aims to improve tumor control and safety.
Rochester, MinnesotaAges 18 years+ - NCT04635657Recruiting
Testing brain function after meningioma surgery
This study measures how thinking and memory change after surgery to remove a meningioma near the front or side of the brain. It may help doctors better understand what to expect and how cognitive recovery can differ from person to person.
Columbus, OhioAges 18–89 - NCT05793034Recruiting
Study factors that predict survival after aggressive meningioma surgery
This study looks at people who had surgery for more aggressive meningiomas (grade 2 or 3) and tries to learn what factors relate to survival. The results may help doctors better predict outcomes for future patients.
RomeAges 18 years+ - NCT06557512Recruiting
Focused radiation after surgery for certain meningiomas
This study tests a type of focused radiation therapy (called stereotactic radiosurgery) given after surgery for certain meningiomas. The goal is to see if this treatment helps prevent the tumor from coming back, and to check its safety.
San Francisco, CaliforniaAges 18 years+ - NCT07418775Recruiting
Meningioma Study: Genes, Health & Life
This study looks at how your tumor's genes, personal health habits, and other factors affect your long-term health after a meningioma diagnosis. You'll be asked to complete surveys about your health and experiences—no new treatments or procedures are involved.
San Francisco, CaliforniaAges 18 years+ - NCT04278118Recruiting
Proton radiation study for non-cancer brain tumor types
This trial tests a radiation plan that gives treatment in fewer, larger “fractions” using proton beams (or sometimes photon beams) for certain non-cancer brain tumor types. It aims to see how well this approach works while keeping side effects manageable.
Atlanta, GeorgiaAges 18 years+ - NCT02523014RecruitingPhase 2
Drug combo for meningioma that keeps growing despite treatment
This Phase 2 trial tests several targeted medicines (given together or by specific assignment) for meningiomas inside the brain that are progressing or not fully removed after surgery. It may help slow the tumor’s growth and improve symptoms by blocking tumor growth pathways.
Birmingham, AlabamaAges 18 years+ - NCT04501705Recruiting
Apatinib for adults with recurring atypical or malignant meningioma
This trial tests whether apatinib can shrink or control recurring atypical/malignant meningioma that has come back after surgery and radiation. It focuses on adults with measurable regrowth on MRI and good overall health to safely take an oral medicine.
Beijing, Beijing MunicipalityAges 18–70 - NCT06640582RecruitingPhase 1/Phase 2
TIL therapy with pembrolizumab for advanced brain cancer
This trial tests a new treatment for advanced brain cancers like glioma and meningioma. It combines your own immune cells (tumor-infiltrating lymphocytes or TILs) with an immunotherapy drug (pembrolizumab) to help your body fight the tumor. It's for people who have tried other treatments without success or have no standard options left.
Beijing, Beijing MunicipalityAges 16–90 - NCT07652762RecruitingPhase 1
IN10018 and dalpiciclib for progressive meningioma
This trial tests a combination of two oral drugs, IN10018 and dalpiciclib, for people with progressive meningioma (a type of brain tumor) that has not responded to standard treatments. The goal is to see if this combination can help shrink or slow the tumor.
Beijing, Beijing MunicipalityAges 18 years+ - NCT07533942RecruitingPhase 2
Testing JZP3507 for Recurrent Grade 2 or 3 Brain Tumors
This study tests a new drug called JZP3507 for people with meningioma (a type of brain tumor, grades 2 or 3) that has come back or grown despite previous treatment. The goal is to see if this medication can slow or shrink the tumor.
San Francisco, CaliforniaAges 18 years+ - NCT07428616RecruitingPhase 2
Study of Zanzalintinib for recurring meningioma
This trial tests a drug called Zanzalintinib for people with meningioma that has come back or grown despite past treatments. It aims to see if the drug can stop or slow tumor growth.
Birmingham, AlabamaAges 18 years+ - NCT07398170Recruiting
Searching for tumor cells in fluid for recurrent meningioma
This study looks for tumor cells in your blood or spinal fluid to see if they can help track aggressive meningiomas that have come back. It may help doctors understand your cancer better and guide future treatments.
Montpellier, FranceAges 18 years+ - NCT06830356Recruiting
PET-guided radiation for high-risk meningiomas
This trial uses a special PET scan to find active tumor areas and then delivers a stronger dose of radiation to those spots. It is for people with aggressive or returning meningiomas who have not had brain radiation before.
Aviano, PordenoneAges 16 years+ - NCT04997317RecruitingPhase 1/Phase 2
Lu-177 targeting drug for returning or growing meningioma
This Phase 1/2 study tests a targeted radioactive medicine (Lu-177-satoreotide) for meningiomas that keep coming back or keep growing. It works only if tumor imaging shows the tumor has the right “target” signal, and it aims to see how well it can control the disease and how safe it is.
Basel, Canton of Basel-CityAges 18 years+ - NCT07150806RecruitingPhase 1/Phase 2
RYZ101 for progressive or recurrent meningioma
This trial is testing an investigational drug, RYZ101, for people with a type of brain tumor called meningioma that has grown back or not responded to other treatments. The goal is to see if RYZ101 can help stop the tumor from growing, and to check its safety. It might be an option if you have already had surgery or radiation.
Columbus, OhioAges 18 years+ - NCT07044076Recruiting
French quality-of-life questionnaire for meningioma patients
This study tests a French version of a questionnaire that measures quality of life in people with meningioma. Participation involves filling out the questionnaire to help doctors better understand how the tumor affects your daily life.
ParisAges 18 years+ - NCT06955169RecruitingPhase 2
Study of lutetium treatment for meningioma after prior therapy
This study tests a radioactive drug, lutetium-177 DOTATATE, against standard care for people whose meningioma has grown despite earlier surgery and radiation. The treatment targets a protein on tumor cells, which may slow or stop growth.
Irvine, CaliforniaAges 18 years+ - NCT06955208Recruiting
Using MRI to Measure Meningioma Stiffness Before Surgery
This study uses a special MRI technique called 3D MRE (magnetic resonance elastography) to measure how stiff a meningioma tumor is. The goal is to see if the stiffness can help predict the tumor’s type and characteristics before surgery.
Shenyang, LiaoningAges 18–80 - NCT06036706Recruiting
Radiation types and thinking skills for skull base meningioma
This study compares different radiation methods for treating a slow-growing, non-cancerous brain tumor at the base of the skull. It aims to see which approach best protects memory and thinking abilities.
CaenAges 20–65 - NCT06752096Recruiting
Robot-Helped Brain Blood Vessel Procedures
This trial uses a robot to assist with brain blood vessel treatments, like checking for blockages, treating tumors, or removing clots. It may help make these procedures more precise and safer.
Seoul, KoreaAges 18–80 - NCT06377371RecruitingPhase 4
Intraoperative tracing of meningioma with copper-64 DOTATATE
This trial tests a special imaging agent called [Cu64]DOTATATE that helps surgeons see meningioma tumors during surgery. It may make tumor removal more complete and safer.
New York, New YorkAges 18–99 - NCT06326190RecruitingPhase 2
Study of radioactive drug for recurrent meningioma
This trial tests a radioactive drug called 177Lu-DOTATATE for people with recurrent meningioma (a type of brain tumor) that has grown after surgery and radiation. The drug targets a protein on the tumor cells and delivers radiation directly to them.
InnsbruckAges 18 years+ - NCT06275919RecruitingPhase 2
Regorafenib for recurring meningioma
This trial tests a pill called regorafenib for people whose meningioma (a brain tumor) has come back and cannot be treated with surgery or radiation. The goal is to see if regorafenib can help stop the tumor from growing further.
Meldola, Forlì-CesenaAges 18 years+
Hear when a new Meningioma trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.
Meningioma trials by city
Studies with a site in or near these metro areas.
Meningioma trials by state
Studies with a site anywhere in these states.
Common questions
- Are there clinical trials for meningioma?
- Yes. Clin2 currently lists 64 recruiting meningioma studies from the U.S. registry, each rewritten for real people, not researchers, so you can see what it’s testing and who it’s for.
- How do I know if I qualify for a meningioma trial?
- Each study lists its eligibility criteria — rules about age, diagnosis, and prior treatments. On every Clin2 trial page we explain these in words written for real people and offer a short, optional pre-screen for a fit read. The study team makes the final decision.
- Does it cost anything to join a meningioma trial?
- Using Clin2 is always free. Many trials cover the cost of the study treatment and related visits; some reimburse travel. The study team explains exactly what’s covered before you decide.
Related conditions
Clin2 helps you find and understand clinical trials and does not provide medical advice. Study data comes from ClinicalTrials.gov. Talk with your doctor about whether a specific trial is right for you.